What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

COPD Clinical Trials 2026: New Inhalers, Anti-Inflammatory Biologics & Lung Repair

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Chronic obstructive pulmonary disease (COPD) affects over 300 million people globally and is the third leading cause of death. Until recently, treatment was largely limited to bronchodilators and inhaled steroids that manage symptoms but don't modify disease progression. In 2026, biologics targeting the inflammatory pathways driving COPD — particularly in patients with eosinophilic inflammation — have reached late-stage trials, and dupilumab received FDA approval for COPD in 2024. This marks a new era for COPD treatment.

Dupilumab for COPD: A Breakthrough

Dupilumab (Dupixent) — already approved for asthma, atopic dermatitis, and other type 2 inflammatory conditions — was approved for COPD with type 2 inflammation (eosinophil count ≥300 cells/μL) in September 2024. The BOREAS and NOTUS Phase 3 trials showed a 30% reduction in exacerbations. In 2026, trials are exploring dupilumab in patients with lower eosinophil counts and in combination with triple inhaler therapy.

Other Biologics in Trials

Itepekimab (anti-IL-33): Phase 3 trials in ex-smokers with COPD showed reduction in exacerbations. Former smokers may benefit more than current smokers due to different inflammatory profiles. Sanofi's AERIFY trials are recruiting.

Tezepelumab (anti-TSLP): Approved for severe asthma, now in Phase 3 for COPD (COURSE trial). TSLP is an epithelial cytokine involved in airway inflammation in both conditions.

Astegolimab (anti-IL-33): Roche's Phase 3 SKYLARK trial in COPD with eosinophilic inflammation is actively recruiting.

Novel Bronchodilators and Combination Inhalers

Ensifentrine (Ohtuvayre), a dual PDE3/PDE4 inhibitor inhaler, was approved in 2024 as the first new bronchodilator class in over 20 years. It provides both bronchodilation and anti-inflammatory effects. Post-marketing trials are comparing it to existing LABA/LAMA combinations and studying its role in triple therapy.

Lung Regeneration Research

Emphysema involves permanent destruction of alveolar tissue. Early-stage research is testing drugs that may promote alveolar regeneration — retinoic acid derivatives, growth factors, and stem cell approaches. These are largely Phase 1/2 and represent longer-term research directions rather than near-term options.

Eligibility for COPD Trials

Most COPD trials require: confirmed COPD diagnosis (post-bronchodilator FEV1/FVC <0.70), spirometry-confirmed severity (FEV1 % predicted), smoking history (≥10 pack-years), history of exacerbations in the past year, and current inhaler therapy. Biologic trials often require blood eosinophil counts — a simple blood test. Stable COPD is required at enrollment (no exacerbation within 4–6 weeks).